Overview

Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial

Status:
Completed
Trial end date:
2018-03-19
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine whether the hepatitis C virus continues to remain unable to be detected in subjects who were previously treated with Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) and achieved sustained virologic response.
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Asunaprevir